Objectives: This paper aims to compare the effectiveness of sacubitril-valsartan and
angiotensin-converting enzyme inhibitor (ACE)/angiotensin receptor blocker (ARB) in …

This review aims to assess the benefits and adverse effects of sacubitril/valsartan in heart
failure, with a focus on important patient outcomes. A systematic review was conducted of …

Abstract Aims Sacubitril/Valsartan (Sac/Val) was proven more effective than enalapril for
symptomatic patients with heart failure (HF) with reduced ejection fraction (HFrEF). This …

Aims We systematically reviewed the European real‐world evidence (RWE) about sacubitril‐
valsartan for heart failure with reduced ejection fraction. Methods and results Twenty‐one …

Background Sacubitril/valsartan is an effective treatment for heart failure with reduced
ejection fraction (HFrEF) based on clinical trial data. However, little is known about its use or …

Aims To compare baseline characteristics of patients with heart failure with reduced ejection
fraction (HFrEF) initiated on sacubitril/valsartan compared with patients continued on …

Introduction Sacubitril/valsartan has been established as an effective treatment for heart
failure (HF) with reduced ejection fraction based on clinical trial data; however, little is known …

Background The impact of sacubitril–valsartan on heart failure (HF) patients with preserved
ejection fractions (HFpEF) is uncertain. The purpose of this meta-analysis was to explore the …

Background The combination drug sacubitril/valsartan was reported to be superior to
enalapril in reducing all-cause death, cardiovascular mortality, and heart failure (HF) …

Objectives To determine efficacy and safety of sacubitril/valsartan compared with enalapril in
Indian patients of PARADIGM-HF trial. Methods A randomized, double-blind, active …